New Research Reveals Phelan-McDermid Syndrome Prevalence Is Significantly Higher Than Previously Estimated

New research conducted by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai suggests that Phelan-McDermid syndrome (PMS) is substantially more common than historical medical estimates indicated. The findings, published in the peer-reviewed journal Autism Research, reveal that the condition likely affects approximately 1 in 7,300 people. This significant upward revision of the prevalence rate suggests that the medical community has been underestimating the reach of this rare genetic disorder, potentially leaving tens of thousands of individuals without a proper diagnosis or access to emerging precision medicine therapies.

Understanding Phelan-McDermid Syndrome

Phelan-McDermid syndrome is a complex genetic disorder primarily caused by a deletion or a pathogenic mutation involving the SHANK3 gene located on chromosome 22. This specific gene plays a critical role in the development of synapses, the connections between neurons that allow for communication within the brain. When SHANK3 function is impaired, it often results in a broad spectrum of medical, intellectual, and behavioral challenges.

The clinical presentation of PMS is highly heterogeneous, meaning it varies significantly from one individual to another. Common characteristics include global developmental delay, moderate to severe intellectual disability, delayed or absent speech, and a high frequency of autism spectrum disorder (ASD) symptoms. It is estimated that changes affecting the SHANK3 gene account for as many as one percent of all diagnosed cases of autism spectrum disorder, marking it as one of the more significant monogenic causes of neurodevelopmental conditions currently identified by researchers.

Chronology and Methodology of the Prevalence Study

For years, clinicians and patient advocacy groups had suspected that the diagnostic numbers for PMS did not reflect the reality of the patient population. To address this discrepancy, the research team at Mount Sinai launched a comprehensive investigation, collaborating with a vast network of genetic testing laboratories, academic medical centers, and prominent autism research programs.

The study design was ambitious, aggregating data from nearly 180,000 individuals with autism who had already undergone genetic testing. The researchers synthesized information from ten distinct sources to ensure a robust dataset. Key partners in this effort included GeneDx, Labcorp, Ambry Genetics, the SPARK research study, the Autism Sequencing Consortium, and several major pediatric hospitals across the United States.

By applying sophisticated statistical models to account for undiagnosed individuals, the limitations of current genetic screening panels, and those individuals with PMS who do not meet the full diagnostic criteria for autism, the team arrived at a prevalence estimate of 13.7 cases per 100,000 people. This data translates to a prevalence rate of roughly 1 in 7,300 individuals. When projected onto the general population of the United States, this suggests that more than 45,000 people may be living with the syndrome, a figure far higher than previous, more conservative estimates.

Addressing the Diagnostic Gap

The stark gap between known clinical cases and the new statistical estimate is a point of significant concern for the medical community. According to Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and a certified genetic counselor at the Seaver Autism Center, the disparity is primarily structural.

"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy noted. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."

This highlights a systemic issue in modern neurology and pediatrics: the underutilization of comprehensive genomic sequencing. When a child presents with developmental delays, clinicians often prioritize symptom management over identifying the underlying genetic etiology. Without a specific genetic diagnosis, patients are often funneled into general developmental support programs rather than receiving targeted care or being enrolled in research programs that could identify them as candidates for clinical trials.

The Imperative of Genetic Testing

The researchers argue that broader access to genetic testing is not merely an academic exercise but a medical necessity. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and senior author of the study, emphasized the shift in mindset required by the medical community.

"We recommend that every child with autism undergo genetic testing, because knowledge is power," Buxbaum said. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."

This sentiment is echoed by industry partners, including Neuren Pharmaceuticals and the advocacy group CureSHANK, both of which provided support for the study. For these organizations, the study represents a shift in the standard of care. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, characterized the identification of these patients as an "ethical imperative." She noted that as new treatments move from the laboratory to the clinical trial phase, the failure to diagnose patients effectively denies them the opportunity to benefit from life-altering medical breakthroughs.

Broader Impact and Implications for Precision Medicine

The publication of this study coincides with a pivotal moment in neurodevelopmental research. Several clinical trials are currently active, testing precision medicine approaches that target the specific biological pathways affected by the SHANK3 deficiency.

For the families of those affected, a diagnosis provides more than just a label for symptoms; it provides a roadmap for specialized care. A confirmed genetic diagnosis can lead to more accurate prognoses, access to support networks, and the opportunity to participate in research studies that explore disease-modifying treatments.

Geraldine Bliss, Board Chair of CureSHANK, highlighted the validation this study provides for the patient community. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."

The study also serves to bolster the "Start Genetic" campaign, a global initiative that encourages health care providers and families to prioritize genetic testing early in the diagnostic process. The underlying philosophy of this movement is that precision medicine—the most promising frontier in treating neurodevelopmental disorders—is entirely dependent on the early and accurate identification of the patient population.

Future Outlook

As the medical community moves toward a future defined by personalized medicine, the lessons learned from the Seaver Autism Center’s investigation are likely to influence diagnostic protocols for years to come. The identification of 45,000 potential cases in the U.S. alone shifts the perception of Phelan-McDermid syndrome from a "rare" curiosity to a significant public health consideration.

The next phase of this research will likely involve improving the accessibility of high-quality genetic sequencing and ensuring that the findings reach primary care pediatricians and neurologists who are on the front lines of autism care. By bridging the gap between genetic discovery and patient identification, the medical field moves one step closer to transforming the landscape of autism treatment, turning the hope of precision therapies into a tangible clinical reality. The collaboration between academic institutions, biotech firms, and patient advocacy groups remains the cornerstone of this progress, ensuring that as science advances, the patients who stand to benefit most are not left behind.